ZNTL – zentalis pharmaceuticals, inc. - common stock (US:NASDAQ)
Stock Stats
News
Zentalis Pharmaceuticals (ZNTL) had its price target raised by Guggenheim from $6.00 to $10.00. They now have a "buy" rating on the stock.
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals (ZNTL) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (ZNTL) was downgraded by Wall Street Zen fro
Form 8-K Zentalis Pharmaceuticals For: Apr 09
Form 10-K Zentalis Pharmaceuticals For: Dec 31
Form 8-K Zentalis Pharmaceuticals For: Mar 26
Form SCHEDULE 13G Zentalis Pharmaceuticals Filed by: Squadron Capital Management LLC
Form 4 Zentalis Pharmaceuticals For: Feb 06 Filed by: Bruns Ingmar
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.